PDF(Pubmed)
Abstract：
UNASSIGNED: Uterine fibroids (UFs) are benign tumors of the female reproductive system originating from the smooth muscle of the uterus. Currently, progesterone is known to play a key role in the differentiation of the myometrial tissue to form UFs and their abnormal growth. The mechanism of action of progesterone in UF tumorigenesis involves its effect on increasing the concentrations and dysregulation of selected growth factors.
UNASSIGNED: A retrospective cohort study was performed to evaluate and compare tumor necrosis factor α (TNF-α), insulin-like growth factor 1 (IGF-1), plasminogen activator inhibitor-1 (PAI-1) serum concentrations in patients with UFs without prior hormonal treatment, patients with UFs treated with a 3-month standard ulipristal acetate (UPA - a type of selective progesterone receptor modulator) scheme (5 mg/day) and in control patients without UFs. A total of 120 patients were divided into 3 groups (controls, UFs with UPA treatment, UFs without UPA treatment).
UNASSIGNED: There were no significant differences in TNF-α serum concentrations between patients with UFs who underwent UPA treatment and patients who did not. Serum concentrations of IGF-1 and PAI-1 did not show significant intergroup differences.
UNASSIGNED: No significant differences were found between TNF-α concentrations in the serum of patients with UFs treated with UPA, and patients without UPA treatment. In addition, our data analysis did not show significant differences in the concentrations of IGF-1 and PAI-1 between patients with UFs and the control group. Further studies on the dependence of specific symptoms on selected growth factors are mandatory.
UNASSIGNED: A retrospective cohort study was performed to evaluate and compare tumor necrosis factor α (TNF-α), insulin-like growth factor 1 (IGF-1), plasminogen activator inhibitor-1 (PAI-1) serum concentrations in patients with UFs without prior hormonal treatment, patients with UFs treated with a 3-month standard ulipristal acetate (UPA - a type of selective progesterone receptor modulator) scheme (5 mg/day) and in control patients without UFs. A total of 120 patients were divided into 3 groups (controls, UFs with UPA treatment, UFs without UPA treatment).
UNASSIGNED: There were no significant differences in TNF-α serum concentrations between patients with UFs who underwent UPA treatment and patients who did not. Serum concentrations of IGF-1 and PAI-1 did not show significant intergroup differences.
UNASSIGNED: No significant differences were found between TNF-α concentrations in the serum of patients with UFs treated with UPA, and patients without UPA treatment. In addition, our data analysis did not show significant differences in the concentrations of IGF-1 and PAI-1 between patients with UFs and the control group. Further studies on the dependence of specific symptoms on selected growth factors are mandatory.
摘要：
■子宫肌瘤（UFs）是女性生殖系统的良性肿瘤，起源于子宫平滑肌。目前,已知孕酮在子宫肌层组织分化形成UF及其异常生长中起关键作用。孕酮在UF肿瘤发生中的作用机制涉及其对增加所选生长因子的浓度和失调的影响。
■进行了一项回顾性队列研究，以评估和比较肿瘤坏死因子α（TNF-α），胰岛素样生长因子1（IGF-1），纤溶酶原激活物抑制剂-1（PAI-1）在UFs患者中的血清浓度，接受3个月标准醋酸乌利司他(UPA-一种选择性孕酮受体调节剂)方案(5mg/天)治疗的UFs患者和无UFs的对照患者.共120例患者分为3组(对照组,UFs与UPA治疗，没有UPA治疗的UFs)。
■接受UPA治疗的UFs患者与未接受UPA治疗的患者之间的TNF-α血清浓度没有显着差异。IGF-1和PAI-1的血清浓度没有显示显著的组间差异。
■在UPA治疗的UFs患者血清中TNF-α浓度之间没有发现显着差异，和没有UPA治疗的患者。此外,我们的数据分析显示,UFs患者和对照组的IGF-1和PAI-1浓度没有显著差异.必须进一步研究特定症状对所选生长因子的依赖性。
■进行了一项回顾性队列研究，以评估和比较肿瘤坏死因子α（TNF-α），胰岛素样生长因子1（IGF-1），纤溶酶原激活物抑制剂-1（PAI-1）在UFs患者中的血清浓度，接受3个月标准醋酸乌利司他(UPA-一种选择性孕酮受体调节剂)方案(5mg/天)治疗的UFs患者和无UFs的对照患者.共120例患者分为3组(对照组,UFs与UPA治疗，没有UPA治疗的UFs)。
■接受UPA治疗的UFs患者与未接受UPA治疗的患者之间的TNF-α血清浓度没有显着差异。IGF-1和PAI-1的血清浓度没有显示显著的组间差异。
■在UPA治疗的UFs患者血清中TNF-α浓度之间没有发现显着差异，和没有UPA治疗的患者。此外,我们的数据分析显示,UFs患者和对照组的IGF-1和PAI-1浓度没有显著差异.必须进一步研究特定症状对所选生长因子的依赖性。
